Abstracts tagged "DMARDs"

Abstract Number: 2891 • 2017 ACR/ARHP Annual Meeting
Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Data on the association between RA and type 2 diabetes mellitus (T2DM) are inconsistent, suggesting RA treatments such as glucocorticoids (GCs) and hydroxychloroquine could…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 1674 • 2017 ACR/ARHP Annual Meeting
Combining Medications That Lower Systemic Oxidative Stress Is Associated with Less Atherosclerosis in Systemic Lupus Erythematosus
Jim C. Oates, Medical Service, Ralph H. Johnson VA Medical Center, Charleston, SC; Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: No single medication has been demonstrated as effective in reducing atherosclerosis or cardiovascular events in systemic lupus erythematosus (SLE), possibly due to the…
Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting
Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Dominick Sudano¹, C. Kent Kwoh², Lili Zhou³, Erin L. Ashbeck⁴ and Wei-Hsuan Lo-Ciganic⁵, ¹University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ⁴The University of Arizona Arthritis Center, Tucson, AZ, ⁵Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ
Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…
Abstract Number: 632 • 2017 ACR/ARHP Annual Meeting
Long-Term Golimumab Retention Rate in Patients with Psoriatic Arthritis. Is Concomitant DMARD Important?
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Juan Gabriel Ovalles-Bonilla⁴, Juan Carlos Nieto², Julia Martínez-Barrio⁵, Iustina Janta², Larissa Valor³, Indalecio Monteagudo² and Francisco Javier López Longo⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in psoriatic arthritis (PsA) patients has been widely documented. The aim of this study was to analyze the…
Abstract Number: 1810 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception
Julia D Flint¹, Maria Mouyis² and Ian Giles³, ¹Medicine, University College London, London, United Kingdom, ²Rheumatology Department, Northwick Park Hospital, London, United Kingdom, ³Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, UK, London, United Kingdom
Background/Purpose: There is limited evidence relating to the impact of disease modifying anti-rheumatic drugs (DMARDs) upon male fertility and on pregnancies conceived by men with rheumatic…
Abstract Number: 152 • 2017 Pediatric Rheumatology Symposium
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
TA Simon¹, A Baheti², N Ray², S Kelly¹ and Z Guo¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is…
Abstract Number: 709 • 2016 ACR/ARHP Annual Meeting
Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Philip J Mease¹, Josef S. Smolen², Dafna D Gladman³, Joachim Sieper⁴, John Weinman⁵, Julia Sommer⁶, Pascal Nurwakagari⁷ and Maja Hojnik⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medical University of Vienna, Vienna, Austria, ³University of Toronto, Toronto, ON, Canada, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵King's College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Ljubljana, Slovenia
Background/Purpose: Adherence to systemic therapies, such as tumor necrosis factor inhibitors (TNFi’s), is affected by various factors and may be critical for optimal disease outcomes…
Abstract Number: 2227 • 2016 ACR/ARHP Annual Meeting
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Andrea Ramirez-Gomez¹, Aldo Barajas-Ochoa¹, Jose Juan Castaneda-Sanchez¹, Jose Dionisio Castillo-Ortiz¹, Jorge M. Sanchez-Gonzalez² and Cesar Ramos-Remus², ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Vicerrectoria Academica, Universidad Autonoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The treatment of rheumatoid arthritis (RA) has evolved continuously. The introduction of non-conventional DMARDs, which include biologic and targeted synthetic DMARDs (tsDMARDs), has been…
Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen², Timo Yli-Kerttula³, Päivi Ekman⁴, Laura Kuusalo⁵, Laura Pirilä⁶, Markku Mali⁷, Marja Puurtinen-Vilkki⁷, Satu Kortelainen⁷, Johanna Paltta⁶, Kirsi Taimen⁷, Markku J. Kauppi⁸, Kari Laiho⁹, Satu Nyrhinen⁹, Heidi Mäkinen¹⁰, Pia Isomäki¹⁰, Terhi Uotila¹⁰, Kalle Aaltonen¹¹, Hannu Kautiainen¹² and Tuulikki Sokka-Isler¹, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁴Satakunta Central Hospital, Rauma, Finland, ⁵Rheumatology, Turku University Central Hospital, Turku, Finland, ⁶Turku University Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Päijät-Häme Central Hospital, Lahti, Finland, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Helsinki University, Helsinki, Finland, ¹²Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
Abstract Number: 1200 • 2016 ACR/ARHP Annual Meeting
Transcriptional Profiling of Early RA Synovial Tissue Reveals the Impact of Triple DMARD Treatment on T Cell Activation Pathways
Alice M Walsh¹, Sunil Nagpal¹, Mihir D Wechalekar², Yanxia Guo¹, Xuefeng Yin¹, Helen Weedon², Susanna Proudman³ and Malcolm D. Smith², ¹Immunology, Janssen Research & Development, Spring House, PA, ²Flinders University, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: While several transcriptional profiling studies of synovial biopsies have been reported from RA patients with advanced disease, there is relatively little data available from…
Abstract Number: 2238 • 2016 ACR/ARHP Annual Meeting
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
Baojin Zhu¹, Lawrence Chang¹, Leilei Qian¹, Cynthia J Larmore¹, Yoko Tanaka² and Andre B. Araujo¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, KS
Background/Purpose: Medications used to manage RA vary in efficacy, safety, and convenience of use. A better understanding of patient preferences of these attributes is key…
Abstract Number: 1350 • 2016 ACR/ARHP Annual Meeting
Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience
Usman Ajaz¹, Jeffrey R. Lisse², Neil M. Ampel³ and Dominick Sudano⁴, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²Arizona Arthritis Center, University of Arizona, Tucson, AZ, ³Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, ⁴Department of Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection that typically causes a self-limited pulmonary illness in the Southwestern United States,. Immunosuppressed patients are at…
Abstract Number: 2460 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
JULIA MARY¹, B Combe², Cédric Lukas³ and Michel De Bandt⁴, ¹RHEUMATOLOGY, CHU Fort de France, 97261, Martinique, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology department, CHU Fort de France, Fort de France, France
Background/Purpose: Early seronegative rheumatoid arthritis (RA) is a separate entity. Less is known about its initial clinical presentation and outcome due to the difficulty in…
Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting
The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants
Marije I. Koenders¹, Monique M. Helsen¹, Birgitte Walgreen¹, Wim B. van den Berg¹, Gianfranco Caselli², Ornella Letari² and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…

« Previous Page
1
…
8
9
10
11
12
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].